Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences (Nasdaq: SLDB) granted 6,580 restricted stock units (RSUs) to one newly hired employee under its 2024 Inducement Stock Incentive Plan. The RSUs vest in four equal annual installments over four years, contingent on continued service, and were approved under Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced it will participate in two upcoming investor conferences focused on healthcare.
President and CEO Bo Cumbo will present at the Jefferies Global Healthcare Conference on June 3, 2026, and at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
Solid Biosciences (Nasdaq: SLDB) reported Q1 2026 results and pipeline progress. Cash, cash equivalents and securities were $380.7 million on March 31, 2026, with runway into H1 2028. Q1 2026 net loss was $56.7 million.
Key updates include first dosing in the Phase 3 IMPACT DUCHENNE trial for SGT-003, 47 participants dosed in Phase 1/2 INSPIRE DUCHENNE, positive EMA Pediatric Investigation Plan opinion, and EU Orphan drug designation. SGT-212 dosed two participants with no serious adverse events, and ARTEMIS for SGT-501 is expected to begin dosing in H2 2026.
Solid Biosciences (Nasdaq: SLDB) dosed the first participant in its multi-country, randomized, placebo-controlled Phase 3 IMPACT DUCHENNE trial of SGT-003 on May 7, 2026. The program complements the Phase 1/2 INSPIRE trial where 46 participants have received SGT-003 and it has been generally well tolerated as of a May 4, 2026 cutoff.
The company received a positive EMA PIP opinion for pediatric development, holds FDA Fast Track, Rare Pediatric and Orphan Drug designations, and was awarded a UK Innovation Passport under ILAP.
Solid Biosciences (Nasdaq: SLDB) granted 8,070 restricted stock units (RSUs) to a newly hired employee on May 1, 2026 as an inducement under Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments through the fourth anniversary, subject to continued service, under the 2024 Inducement Stock Incentive Plan.
Solid Biosciences (Nasdaq: SLDB) will present its largest scientific program at the 29th ASGCT Annual Meeting in Boston, May 11–15, 2026. The company will deliver 16 presentations (5 oral, 11 posters) covering clinical updates, next-generation delivery, capsid engineering and scalable AAV manufacturing.
Solid Biosciences (Nasdaq: SLDB) announced the European Commission has granted Orphan Drug designation to SGT-003 for Duchenne muscular dystrophy on April 28, 2026. The designation follows EMA positive opinion and complements the U.K. ILAP Innovation Passport and prior U.S. Fast Track, Orphan Drug, and Rare Pediatric Disease designations.
SGT-003 is in two ongoing trials: the Phase 1/2 INSPIRE DUCHENNE study and the Phase 3 randomized IMPACT DUCHENNE trial as part of a coordinated multinational development plan.
Solid Biosciences (Nasdaq: SLDB) will participate in investor conferences in April 2026. President and CEO Bo Cumbo will join a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 2:15 pm ET.
Management will hold one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026. A live webcast of the April 14 presentation will be available on the company’s Investors Events page, with the replay archived for 90 days.
Solid Biosciences (Nasdaq: SLDB) reported Q4 and full-year 2025 results and clinical progress on March 19, 2026. Key updates: SGT-003 showed positive interim Phase 1/2 INSPIRE data in 41 dosed participants and Phase 3 IMPACT dosing expected in April 2026. SGT-212 and SGT-501 advanced into Phase 1b studies. Financials: $187.9M cash at 12/31/25; completed a $240M private placement in March 2026, extending runway into H1 2028; 2025 net loss $174.3M and R&D $140.3M.
Solid Biosciences (NASDAQ: SLDB) reported interim positive Phase 1/2 INSPIRE DUCHENNE results for SGT-003 on March 11, 2026, with 40 participants dosed as of that date. Data show robust microdystrophin expression, restoration of DAPC components (beta-sarcoglycan, nNOS), biomarker improvements, and stabilization-to-improvement in LVEF; safety remained generally favorable. The company plans additional FDA meetings in H1 2026 to discuss a potential accelerated approval pathway and will provide a mid-2026 update.